Iovance Biotherapeutics
The Senior Manager, Market Access Marketing at Iovance Biotherapeutics leads the tactical execution of the U.S. market access strategy for AMTAGVI and pipeline therapies. This role involves translating clinical and economic evidence into differentiated value messaging for payers and providers, while managing cross-functional partnerships and field team enablement. The position requires developing payer and provider resources, generating market insights, and ensuring compliant execution of market access initiatives.
Headquarters
San Carlos, California, United States
Company Size
501-1000 employees
Founded
2007
Iovance Biotherapeutics is a clinical-stage biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors. Its lead product Amtagvi (lifileucel) is being investigated in multiple clinical trials, with manufacturing conducted at the Iovance Cell Therapy Center in Philadelphia, PA, and collaborations with academic and industry partners to advance next-generation TIL platforms.
Iovance Biotherapeutics’ Latest Moves Shape Market Outlook
7 hours ago
A Look At Iovance Biotherapeutics (IOVA) Valuation After Sharp Recent Share Price Momentum
3 days ago
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Iovance Biotherapeutics.
Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years
1 week ago